Focuses on characterizing genetic mouse models and identifying robust and reproducible behavioral phenotypes in order to identify translatable endpoints for assessing novel therapeutic agents.
Dr. Stacey J Sukoff Rizzo is an Associate Director of The Jackson Laboratory’s Center for Biometric Analysis and Director of The Jackson Laboratory’s Mouse Neurobehavioral Phenotyping Facility. Dr. Rizzo is a behavior pharmacologist by training and holds a BS in Animal Sciences from Rutgers University and a PhD in Neuroscience from University College London. Prior to joining The Jackson Laboratory in 2014, Dr. Rizzo held positions in the pharmaceutical industry in Neuroscience Drug Discovery departments at Wyeth Ayerst Research, Merck Research Laboratories, Aventis Pharmaceuticals, and Pfizer where she led and contributed to many drug discovery projects across therapeutic areas. During her tenure with Pfizer, Dr. Rizzo served as Principal Scientist and Interim Head of Pfizer’s Autism In Vivo Group and Group Leader of Pfizer’s Neurobehavioral Core where she was responsible for identifying robust and reliable behavioral phenotypes in animal models of Neuropsychiatric (depression, anxiety, schizophrenia), Neurodegenerative (Alzheimer’s, Parkinsons, and Huntington’s Diseases), Autism Spectrum Disorders and Addiction that could be employed to assess the utility of novel therapeutic agents. Dr. Rizzo is an internationally recognized expert in behavioral phenotyping of mouse models of disease.